P1NP is a useful bone turnover marker that Dr. Tanner checks to monitor #osteoporosis therapy (if insurance covers it) - it is not affected by diurnal variation, food, renal function. #ACR22 @rheumnow #ACRReview
ACR 2022 Tweet by TheDaoIndex
TweetRelated Content
Betsy Kirchner, DNP, shares practical tips for managing metabolic bone disease, including the importance of VFA imaging to catch asymptomatic vertebral fractures and utilizing fracture liaison services to close care gaps. She highlights key pearls like the doubled fracture risk in RA patients, ACR's risk stratification for glucocorticoid-induced osteoporosis, and a simple FRAX adjustment calculation that can improve treatment decisions.
As rheumatologists, most of us manage osteoporosis in some form every single day. We have newer agents, newer sequencing strategies, and an increasing number of patients asking for “less medicinal” options that go beyond a prescription. At RWCS, Dr. Gina Woods opened her talk by reframing osteoporosis as a comprehensive approach to bone and muscle health rather than a narrow discussion about a DEXA report.
